These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

114 related items for PubMed ID: 20727879

  • 1. Effect of the cannabinoid receptor-1 antagonist rimonabant on lipolysis in rats.
    Mølhøj S, Hansen HS, Schweiger M, Zimmermann R, Johansen T, Malmlöf K.
    Eur J Pharmacol; 2010 Nov 10; 646(1-3):38-45. PubMed ID: 20727879
    [Abstract] [Full Text] [Related]

  • 2. The cannabinoid CB1 receptor inverse agonist, rimonabant, modifies body weight and adiponectin function in diet-induced obese rats as a consequence of reduced food intake.
    Thornton-Jones ZD, Kennett GA, Benwell KR, Revell DF, Misra A, Sellwood DM, Vickers SP, Clifton PG.
    Pharmacol Biochem Behav; 2006 Jun 10; 84(2):353-9. PubMed ID: 16814374
    [Abstract] [Full Text] [Related]

  • 3. Effects on food intake and blood lipids of cannabinoid receptor 1 antagonist treatment in lean rats.
    Bennetzen MF, Nielsen MP, Richelsen B, Pedersen SB.
    Obesity (Silver Spring); 2008 Nov 10; 16(11):2451-5. PubMed ID: 18719671
    [Abstract] [Full Text] [Related]

  • 4. Increased energy expenditure contributes more to the body weight-reducing effect of rimonabant than reduced food intake in candy-fed wistar rats.
    Herling AW, Kilp S, Elvert R, Haschke G, Kramer W.
    Endocrinology; 2008 May 10; 149(5):2557-66. PubMed ID: 18276749
    [Abstract] [Full Text] [Related]

  • 5. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN, Joharapurkar AA, Patel V, Kshirsagar SG, Bahekar R, Srivastava BK, Jain MR.
    Can J Physiol Pharmacol; 2014 Dec 10; 92(12):975-83. PubMed ID: 25361428
    [Abstract] [Full Text] [Related]

  • 6. A novel peripheral cannabinoid receptor 1 antagonist, BPR0912, reduces weight independently of food intake and modulates thermogenesis.
    Hsiao WC, Shia KS, Wang YT, Yeh YN, Chang CP, Lin Y, Chen PH, Wu CH, Chao YS, Hung MS.
    Diabetes Obes Metab; 2015 May 10; 17(5):495-504. PubMed ID: 25656402
    [Abstract] [Full Text] [Related]

  • 7. Anti-obesity effects of the combined administration of CB1 receptor antagonist rimonabant and melanin-concentrating hormone antagonist SNAP-94847 in diet-induced obese mice.
    Verty AN, Lockie SH, Stefanidis A, Oldfield BJ.
    Int J Obes (Lond); 2013 Feb 10; 37(2):279-87. PubMed ID: 22473329
    [Abstract] [Full Text] [Related]

  • 8. Tolerance to hypophagia induced by prolonged treatment with a CB1 antagonist is related to the reversion of anorexigenic neuropeptide gene expression in the hypothalamus.
    Rorato R, Miyahara C, Antunes-Rodrigues J, Elias LL.
    Regul Pept; 2013 Mar 10; 182():12-8. PubMed ID: 23327999
    [Abstract] [Full Text] [Related]

  • 9. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance.
    Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Péleraux A, Pénarier G, Soubrié P, Le Fur G, Galiègue S, Casellas P.
    FASEB J; 2005 Sep 10; 19(11):1567-9. PubMed ID: 16009704
    [Abstract] [Full Text] [Related]

  • 10. Effects of rimonabant, a cannabinoid CB1 receptor ligand, on energy expenditure in lean rats.
    Kunz I, Meier MK, Bourson A, Fisseha M, Schilling W.
    Int J Obes (Lond); 2008 May 10; 32(5):863-70. PubMed ID: 18253160
    [Abstract] [Full Text] [Related]

  • 11. Effect of rimonabant, the cannabinoid CB1 receptor antagonist, on peripheral nerve in streptozotocin-induced diabetic rat.
    Liu WJ, Jin HY, Park JH, Baek HS, Park TS.
    Eur J Pharmacol; 2010 Jul 10; 637(1-3):70-6. PubMed ID: 20406631
    [Abstract] [Full Text] [Related]

  • 12. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells.
    Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F, Soubrié P.
    Mol Pharmacol; 2003 Apr 10; 63(4):908-14. PubMed ID: 12644592
    [Abstract] [Full Text] [Related]

  • 13. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes.
    Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M.
    Mol Pharmacol; 2006 Feb 10; 69(2):471-8. PubMed ID: 16282221
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: preclinical and clinical data.
    Carai MA, Colombo G, Maccioni P, Gessa GL.
    CNS Drug Rev; 2006 Feb 10; 12(2):91-9. PubMed ID: 16958983
    [Abstract] [Full Text] [Related]

  • 15. Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism.
    Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S.
    Obesity (Silver Spring); 2009 Aug 10; 17(8):1641-5. PubMed ID: 19325539
    [Abstract] [Full Text] [Related]

  • 16. Blockade of cannabinoid CB1 receptors improves renal function, metabolic profile, and increased survival of obese Zucker rats.
    Janiak P, Poirier B, Bidouard JP, Cadrouvele C, Pierre F, Gouraud L, Barbosa I, Dedio J, Maffrand JP, Le Fur G, O'Connor S, Herbert JM.
    Kidney Int; 2007 Dec 10; 72(11):1345-57. PubMed ID: 17882151
    [Abstract] [Full Text] [Related]

  • 17. The effects of rimonabant on brown adipose tissue in rat: implications for energy expenditure.
    Verty AN, Allen AM, Oldfield BJ.
    Obesity (Silver Spring); 2009 Feb 10; 17(2):254-61. PubMed ID: 19057531
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats.
    Dyr W, Ligieza J, Kostowski W.
    Alcohol; 2008 Sep 10; 42(6):509-12. PubMed ID: 18504086
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.